{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:10:59Z","timestamp":1758892259409,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"COLOSYS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Treating patients with combinations of drugs that have synergistic effects has become widespread practice in the clinic. Drugs work synergistically when the observed effect of a drug combination is larger than the effect predicted by the reference model. The reference model is a theoretical null model that returns the combined effect of given doses of drugs under the assumption that these drugs do not interact. There is ongoing debate on what it means for drugs to not interact. The controversy transcends mathematical punctuality, as different non-interaction principles result in different reference models. A famous reference model that has been in existence for already a long time is Loewe\u2019s reference model. Loewe\u2019s vision on non-interaction was purely intuitive: two drugs do not interact if all combinations of doses that result in a certain given effect lie on a straight line.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We show that Loewe\u2019s reference model can be obtained from much more fundamental principles. First, we introduce the new notion of complementary dose. Secondly, we reformulate the existing concept of equivalent dose, whereby our formulation is more general than existing ones. Finally, a very general non-interaction principle is put forward. The proposed non-interaction principle represents a certain interplay between complementary and equivalent doses: drugs are non-interacting if complementarity is preserved under equivalence. It is then shown that Loewe\u2019s reference model naturally follows from these principles by an appropriate choice of complementarity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The presented work increases insight into Loewe\u2019s reference model for drug combinations, which is realized by the introduction of a very general non-interaction principle that does not refer to any specific dose-response curve, nor to any property of applicable dose-response curves.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12859-020-03771-4","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T20:02:46Z","timestamp":1602792166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A foundation for reference models for drug combinations with an application to Loewe\u2019s reference model"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1104-0668","authenticated-orcid":false,"given":"Wim","family":"De Mulder","sequence":"first","affiliation":[]},{"given":"Martin","family":"Kuiper","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"3771_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 2015;13:504\u201313.","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"3771_CR2","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","volume":"34","author":"K Preuer","year":"2018","unstructured":"Preuer K, Lewis RPI, Hochreiter S, et al. DeepSynergy: predicting anti-cancer drug synergy with deep learning. Bioinformatics. 2018;34:1538\u201346.","journal-title":"Bioinformatics"},{"key":"3771_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-161068","volume":"56","author":"S Matsunaga","year":"2017","unstructured":"Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson\u2019s disease: a meta-analysis. J. Alzheimers. Dis. 2017;56:1229\u201339.","journal-title":"J. Alzheimers. Dis."},{"key":"3771_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr. Opin. Virol. 2016;18:50\u20136.","journal-title":"Curr. Opin. Virol."},{"key":"3771_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1586\/eri.11.125","volume":"9","author":"A Scourfield","year":"2011","unstructured":"Scourfield A, Waters L, Nelson M. Drug combinations for HIV: what\u2019s new? Expert. Rev. Anti Infect. Ther. 2011;9:1001\u201311.","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"3771_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1086\/595701","volume":"48","author":"LE Wilson","year":"2009","unstructured":"Wilson LE, Gallant JE, Mayer KH. The management of treatment-rxperienced HIV-infected patients: new drugs and drug combinations. Clin. Infect. Dis. 2009;48:214\u201321.","journal-title":"Clin. Infect. Dis."},{"key":"3771_CR7","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.rmed.2007.04.017","volume":"101","author":"M Breton","year":"2007","unstructured":"Breton M, Lelorier J, Forget A, Blais L. Use of combination therapy in asthma: are they prescribed according to guidelines. Respir. Med. 2007;101:1916\u201323.","journal-title":"Respir. Med."},{"key":"3771_CR8","first-page":"217","volume":"22","author":"HS Nelson","year":"2001","unstructured":"Nelson HS. Combination therapy of bronchial asthma. Allergy Asthma Proc. 2001;22:217\u201320.","journal-title":"Allergy Asthma Proc."},{"key":"3771_CR9","first-page":"375","volume":"4","author":"I Ruggeri","year":"2012","unstructured":"Ruggeri I, Bragato D, Colombo GL, et al. Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy. Clinicoecon. Outcomes Res. 2012;4:375\u201382.","journal-title":"Clinicoecon. Outcomes Res."},{"key":"3771_CR10","first-page":"238","volume":"17","author":"JA Saleh","year":"2008","unstructured":"Saleh JA. Combination therapy in asthma: a review. Niger. J. Med. 2008;17:238\u201343.","journal-title":"Niger. J. Med."},{"key":"3771_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coph.2018.07.008","volume":"42","author":"T Pemovska","year":"2018","unstructured":"Pemovska T, Bigenzahn JW, Superti-Furga G. Recent advances in combinatorial drug screening and synergy scoring. Curr. Opin. Pharmacol. 2018;42:102\u201310.","journal-title":"Curr. Opin. Pharmacol."},{"key":"3771_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12976-017-0060-y","volume":"14","author":"M Schindler","year":"2017","unstructured":"Schindler M. Theory of synergistic effects: Hill-type response surfaces as \u2018null-interaction\u2019 models for mixtures. Theor. Biol. Med. Model. 2017;14:15.","journal-title":"Theor. Biol. Med. Model."},{"key":"3771_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI. The toxicity of poisons applied jointly. Ann. Appl. Biol. 1939;26:585\u2013615.","journal-title":"Ann. Appl. Biol."},{"key":"3771_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"3771_CR15","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/bioinformatics\/btx161","volume":"33","author":"\u00c5 Flobak","year":"2017","unstructured":"Flobak \u00c5, Vazquez M, L\u00e6greid A, Valencia A. CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets. Bioinformatics. 2017;33:2410\u20132.","journal-title":"Bioinformatics"},{"key":"3771_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF02322290","volume":"27","author":"S Loewe","year":"1928","unstructured":"Loewe S. Die quantitativen probleme der pharmakologie. Ergebnisse Physiol. 1928;27:47\u2013187.","journal-title":"Ergebnisse Physiol."},{"key":"3771_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fphar.2018.00031","volume":"9","author":"S Lederer","year":"2018","unstructured":"Lederer S, Dijkstra T, Heskes T. Additive dose response models: explicit formulation and the Loewe additivity consistency condition. Front. Pharmacol. 2018;9:31.","journal-title":"Front. Pharmacol."}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-020-03771-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T14:00:17Z","timestamp":1634306417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-020-03771-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1186\/s12859-020-03771-4","relation":{},"ISSN":["1471-2105"],"issn-type":[{"type":"electronic","value":"1471-2105"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}